Blood vessel inhibitors have been pursued as anticancer agents, but in low doses they may actually promote blood-vessel formation and tumour growth in mice. The results, published online in Nature Medicine, call for a reassessment of these inhibitors as anticancer agents, with implications for their potential use in humans.
Certain inhibitors of integrins -- cell surface receptors that define cellular shape, mobility, and regulate the cell cycle -- have entered clinical trials as agents for cancer treatment, owing to their ability to prevent angiogenesis (blood-vessel growth), but their success has been limited. Andrew Reynolds, Kairbaan Hodivala-Dilke and their colleagues show that low concentrations of integrin inhibitors can paradoxically stimulate tumour growth and tumour angiogenesis by altering the trafficking of one specific integrin and of a well known proangiogenic molecule. Author contact: Andrew Reynolds (Institute of Cancer Research, London, UK) E-mail: andrew.reynolds@icr.ac.uk Kairbaan Hodivala-Dilke (Cancer Research UK, London, UK) E-mail: andrew.reynolds@icr.ac.uk Abstract available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
|